-
Q&A with Candriam’s Thomson: A science-led, transparent regulatory process is key for biotech sector
Cuts to US FDA funding are fuelling fears of delays to drug approvals that could kickstart a biotech stock selloff
-
Q&A with TNC’s Heffernan: Financial institutions are failing to price in commodity market volatility
Finance ‘is the oxygen of commodities’ and should be leveraged to address deforestation risk
-
Q&A with Parmenion’s Mollie Thornton: Negative ESG narrative surrounding Trump is overdone
Surprisingly, there is plenty of overlap between the Trump administration priorities and sustainable investing
-
Q&A with Michele Demers: Where is the money going in sustainable investment?
While the terminology is evolving – funds move away from ‘ESG’ – the commitment to sustainability remains strong
-
Q&A with Insight Investment’s Soens: PCAF carbon footprint guidance represents ‘meaningful progress’
The guidance has implications not just for green bond holdings, but for conventional bond and equity portfolios as well
-
Q&A with Morningstar’s Edwards: DeepSeek and AI’s impact on climate indices
Rob Edwards discusses Morningstar’s latest index update and looks ahead at the wider impacts of a potential AI arms race
-
First Sentier Investors’ Lee: Action we are taking to meet our ambitious nature targets
Joanne Lee shares the firms’ progress on its new nature targets and her predictions for future nature-related themes
-
Rebalance Earth’s Gardner: ‘When ecosystems fail, economies falter’
Nature Transition Plans can provide a framework for tackling the risks posed by the degradation of the natural world
-
Q&A with CCLA’s James Corah: Rebuilding sustainable investment
CCLA’s head of sustainability discusses the company’s five-point plan that values engagement and focuses on real-world change
